TC Medical(SH:600763) Chang Jiang Shang Bao·2026-02-24 23:46Core Viewpoint - Tongce Medical's executives are planning to repurchase shares, reflecting their confidence in the company's future growth and long-term investment value [1][5]. Group 1: Share Repurchase Plan - The executives, including Chairman Wang Yi and other senior management, plan to increase their holdings between February 13, 2026, and August 13, 2026, with a total investment of no less than 6 million yuan and up to 12 million yuan [1][4]. - The specific amounts for individual executives include Wang Yi, Huang Yuhua, and Zhang Hua each planning to invest between 1.5 million to 3 million yuan, while CFO Xu Guoxi plans to invest 500,000 to 1 million yuan, and Zhao Min plans to invest 1 million to 2 million yuan [1][4]. Group 2: Recent Share Purchases - As of February 13, 2026, the executives have already purchased a total of 38,200 shares for approximately 1.82 million yuan [2][4]. - The breakdown of recent purchases includes Wang Yi buying 10,500 shares for 499,600 yuan, Huang Yuhua buying 10,000 shares for 476,100 yuan, and Zhang Hua buying 10,000 shares for 473,300 yuan [3][4]. Group 3: Company Performance and Future Outlook - Tongce Medical's stock price has seen fluctuations, dropping to 35.54 yuan per share in April 2024 but recovering to 50.03 yuan per share by February 24, 2026, with a total market capitalization of 22.38 billion yuan [2][5]. - The company aims for a 30% year-on-year growth in overall performance for 2026, supported by ongoing reforms and an internal revenue doubling plan [2][7]. - For the first three quarters of 2025, Tongce Medical reported revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit of 514 million yuan, up 3.16% [7].